Get the Stockscreener App
14.84
2.98%
0.43
After Hours:
14.55
-0.29
-1.95%
Takeda Pharmaceutical Co Adr stock is traded at $14.84, with a volume of 3.41M.
It is up +2.98% in the last 24 hours and up +12.00% over the past month.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
See More
Previous Close:
$14.41
Open:
$14.575
24h Volume:
3.41M
Relative Volume:
2.00
Market Cap:
$47.70B
Revenue:
$30.25B
Net Income/Loss:
$1.37B
P/E Ratio:
34.86
EPS:
0.4257
Net Cash Flow:
$5.08B
1W Performance:
+5.40%
1M Performance:
+12.00%
6M Performance:
-0.54%
1Y Performance:
+1.92%
1-Day Range:
$14.55
$15.05
1-Week Range:
$14.27
$15.05
52-Week Range:
$12.57
$15.08
Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile
Compare TAK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TAK
Takeda Pharmaceutical Co Adr
|
14.84 | 47.70B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
ZTS
Zoetis Inc
|
170.53 | 75.15B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.58 | 47.71B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.00 | 18.75B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.28 | 13.96B | 612.78M | -86.37M | -62.91M | -0.87 |
Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-19-22 | Upgrade | Cowen | Market Perform → Outperform |
| Oct-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-19-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-19 | Initiated | Cowen | Market Perform |
| Aug-15-19 | Downgrade | Daiwa Securities | Outperform → Neutral |
View All
Takeda Pharmaceutical Co Adr Stock (TAK) Latest News
JAK Inhibitors Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight - GlobeNewswire Inc.
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
XFOR: Receives €28.5 Upfront for Licensing Agreement with Norgine… - MSN
TAK vs. DSNKY: Which Stock Is the Better Value Option? - Nasdaq
Ex-Intern Becomes Billionaire in Australia Pharmacy Merger - MSN
IgA nephropathy Clinical Trials and Pipeline 2025: EMA, PDMA, - openPR
IgA nephropathy Clinical Trials and Pipeline Assessment: EMA, - openPR
Procter & Gamble Co (PG) expanding its growth trajectory ahead - SETE News
Prepare Yourself for Liftoff: AMKOR Technology Inc (AMKR) - SETE News
Takeda Pharmaceutical Co ADR [TAK] President, Plasma-Derived Ther makes an insider purchase of 19,073 shares worth 0.28 million. – Knox Daily - Knox Daily
Advanced Drainage Systems Inc [WMS] Records 50-Day SMA of $122.78 - Knox Daily
GFL Shares Experience Surge in Value - Knox Daily
UBS Group AG [UBS] Shares Rise 2.39 % on Thursday - Knox Daily
Takeda Pharmaceutical Co ADR (TAK)’s stock price range in the last year - US Post News
Inmode Ltd (INMD) Stock Price and Analyst Predictions - The News Heater
Recent Insider Activity Could Benefit Wabash National Corp (WNC) - Knox Daily
Analyzing Takeda Pharmaceutical Co ADR (TAK) After Recent Trading Activity - Knox Daily
Ascentage Has First U.S. Biotech IPO of 2025, Raising $126M to Bring Its Cancer Meds to the World - Dealbreaker
Keros Therapeutics seals $200M deal with Takeda - Investing.com
Japan’s Takeda launches innovation centre in Bengaluru; to hire 750 in 2025 - Deccan Herald
Weekly Upgrades and Downgrades - InvestorPlace
Amgen stock price formed a death cross: will it rebound in 2025? - MSN
Saudi Arabia Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
USFDA gives tentative approval to Lupin’s generic formulation to treat type 2 diabetes - The Financial Express
Dr. Kevan Jacobson and Dr. Genelle Lunken Awarded $1M Pioneer Grant for Transformative Pediatric Research in Inflammatory Bowel Disease - Quantisnow
Things To Consider Before You Buy Takeda Pharmaceutical Co ADR (NYSE: TAK) - Stocks Register
Capital One Financial Corp (NYSE: COF): Overvalued In Comparison To Others? - Stocks Register
Takeda and Alloy Therapeutics partner to make off-the-shelf CAR-T therapies - MSN
Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform - Quantisnow
Australia Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
Denmark Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
Takeda Pharmaceutical Co Adr Stock (TAK) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.93%
2.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):